Dicloxacillin

Dicloxacillin
Clinical data
AHFS/Drugs.com	Monograph
MedlinePlus	a685017
Pregnancy; category	AU: B2; ;
Routes of; administration	Oral
ATC code	J01CF01 (WHO) QJ51CF01 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	60 to 80%
Protein binding	98%
Metabolism	Hepatic
Elimination half-life	0.7 hours
Excretion	Renal and biliary
Identifiers
	IUPAC name (2S,5R,6R)-6-{[3-(2,6-dichlorophenyl)-5-methyl-; oxazole-4-carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-; 1-azabicyclo[3.2.0]heptane-2-carboxylic acid;
CAS Number	3116-76-5 ;
PubChem CID	18381;
DrugBank	DB00485 ;
ChemSpider	17358 ;
UNII	COF19H7WBK;
KEGG	D02348 ;
ChEBI	CHEBI:4511 ;
ChEMBL	ChEMBL893 ;
CompTox Dashboard (EPA)	DTXSID1022924 ;
ECHA InfoCard	100.019.535
Chemical and physical data
Formula	C19H17Cl2N3O5S
Molar mass	470.32 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)c2c(onc2c1c(Cl)cccc1Cl)C)[C@H]4SC3(C)C;
	InChI InChI=1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1 ; Key:YFAGHNZHGGCZAX-JKIFEVAISA-N ;
	(verify)

Dicloxacillin is a narrow-spectrum β-lactam antibiotic of the penicillin class.^[1] It is used to treat infections caused by susceptible (non-resistant) Gram-positive bacteria.^[1] It is active against beta-lactamase-producing organisms such as Staphylococcus aureus, which would otherwise be resistant to most penicillins. Dicloxacillin is available under a variety of trade names including Diclocil (BMS).^[2]

It was patented in 1961 and approved for medical use in 1968.^[3] It is available as a generic medication.^[4]

^ ^a ^b Product Information: DICLOXACILLIN SODIUM-dicloxacillin sodium capsule. Teva Pharmaceuticals USA Inc, Revised 8/2015
^ Miranda-Novales G, Leaños-Miranda BE, Vilchis-Pérez M, Solórzano-Santos F (October 2006). "In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strains". Annals of Clinical Microbiology and Antimicrobials. 5: 25. doi:10.1186/1476-0711-5-25. PMC 1617116. PMID 17034644.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 491. ISBN 9783527607495.
^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.